Eli Lilly and (LLY) Stock Rating Reaffirmed by Credit Suisse Group

Eli Lilly and (NYSE:LLY)‘s stock had its “hold” rating restated by equities researchers at Credit Suisse Group in a research report issued to clients and investors on Wednesday.

A number of other research firms have also commented on LLY. Morgan Stanley set a $86.00 price objective on shares of Eli Lilly and and gave the company a “hold” rating in a research report on Friday, October 6th. Leerink Swann raised their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, October 24th. Goldman Sachs Group restated a “buy” rating and issued a $95.00 price objective (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a research report on Friday, October 13th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. Eli Lilly and currently has an average rating of “Hold” and an average price target of $90.25.

Shares of Eli Lilly and (NYSE:LLY) traded up $0.04 during trading hours on Wednesday, reaching $86.71. 4,252,500 shares of the company’s stock were exchanged, compared to its average volume of 3,674,671. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The company has a market capitalization of $95,431.91, a price-to-earnings ratio of 21.19, a PEG ratio of 1.90 and a beta of 0.35. Eli Lilly and has a 12-month low of $67.54 and a 12-month high of $89.09.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the business earned $0.88 earnings per share. sell-side analysts expect that Eli Lilly and will post 4.21 EPS for the current year.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 190,000 shares of Eli Lilly and stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the completion of the sale, the insider now directly owns 123,682,287 shares in the company, valued at $10,207,499,146.11. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 628,588 shares of company stock valued at $53,399,536. 0.20% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in LLY. Pathstone Family Office LLC raised its stake in shares of Eli Lilly and by 100.0% during the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after acquiring an additional 29 shares in the last quarter. Vantage Financial Partners Ltd. Inc. purchased a new position in shares of Eli Lilly and during the second quarter worth approximately $494,000. Acrospire Investment Management LLC raised its stake in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC purchased a new position in shares of Eli Lilly and during the second quarter worth approximately $128,000. Finally, San Francisco Sentry Investment Group CA purchased a new position in shares of Eli Lilly and during the second quarter worth approximately $129,000. Institutional investors and hedge funds own 76.42% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/13/eli-lilly-and-lly-stock-rating-reaffirmed-by-credit-suisse-group.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply